Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arkansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arkansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arkansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Matthew Lockwood (NPI 1265875470)

Field	Value
Entity Type	Individual
Organization	Matthew Lockwood
Address	3232 N Northhills Blvd
City	Fayetteville
State	AR
ZIP	72703
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	April 8, 2013

Payer Source	Total Paid
Medicare	$4.2M
Medicaid	$0

Key Findings

MATTHEW LOCKWOOD is a Hematology & Oncology physician with lifetime Medicare revenue of $4.2M and no Medicaid billing on file; this makes the practice effectively Medicare‑focused for reported public payers. The NPI was enumerated 2013-04-08 (~13 years ago), indicating an established billing history of roughly the past decade-plus.

Revenue is highly concentrated in three high-cost oncology agents: J9271 (pembrolizumab) contributed $920.2K (23.6%), J9299 (nivolumab) contributed $570.7K (14.7%), and J9144 (daratumumab) contributed $479.5K (12.3%); the precomputed top‑3 codes by revenue account for 50.6% of this provider's total Medicare revenue. This concentration signals dependence on a small set of systemic cancer therapies for the majority of Medicare receipts.

The procedural and drug mix shows a full-service oncology infusion practice with a strong emphasis on immunotherapy and targeted agents: high revenue from J9271, J9299, and J9144 is complemented by chemotherapy administration (96413, $61.5K) and supportive/adjunctive medications such as J1561 immune globulin ($263.3K) and J0897 denosumab ($133.9K). The presence of A9607 (lutetium therapeutic, $460.8K, 11.8%) and diagnostic radiopharmaceuticals A9596 (gallium Ga-68, $139.1K) indicates the practice also bills theranostics and advanced molecular imaging.

Competitive standing for the top biologic drugs is generally in the ‘typical, unremarkable volume’ band rather than dominant national leadership: J9271 ranks #328 of 1841 (82th percentile; typical, unremarkable volume), J9299 ranks #116 of 505 (77th percentile; typical, unremarkable volume), and J9144 ranks #121 of 615 (80th percentile; typical, unremarkable volume). At the same time, certain service lines show above‑typical intensity—office E/M 99214 ($87.4K) ranks at the 97th percentile and chemotherapy administration 96413 ranks at the 96th percentile, both described as “notably above typical national volume,” suggesting a high volume of complex outpatient encounters and treatment administration.

Imaging and diagnostic utilization stands out: 78815 PET/CT ($236.1K, 6.1%) is in the 87th percentile (typical, unremarkable volume), while CT abdomen/pelvis 74178 ($35.6K) is labeled an “extreme outlier, far above typical national volume” at the 99th percentile. Together with A9596 and A9552 radiopharmaceutical billing, this pattern points to substantial use of advanced imaging and molecular diagnostics—consistent with integrated diagnostic/therapeutic oncology services.

The practice demonstrates active use of biosimilars and supportive agents alongside originator biologics: Q5115 (rituximab biosimilar) produced $113.9K (2.9%) and Q5118 (bevacizumab biosimilar) produced $52.3K (1.3%), while epoetin products (J0885 and Q5106) and pegfilgrastim biosimilar Q5108 also appear in the top codes. This mix suggests operational emphasis on cost-managed biologic sourcing and routine supportive care for systemic therapy patients.

Payer mix concentration is a strategic exposure: with $4.2M in Medicare revenue and “none below” for Medicaid, the provider is effectively single‑payer (Medicare) in the public claims data—this can concentrate reimbursement risk and contracting leverage around Medicare fee schedules and policies. Analysts should treat Medicaid network/volume as absent in the available data rather than merely low.

Tenure and billing footprint together imply an established oncology infusion practice that combines high-cost checkpoint inhibitors with theranostic treatments and heavy imaging use. The NPI age (~13 years) plus multiple codes in very high national percentiles for E/M, chemotherapy administration, and certain imaging CPTs supports an interpretation of a mature outpatient oncology operation with specialized therapeutic capabilities rather than a low‑volume generalist practice.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

132 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	21,400	$40	$920.2K
J9299	Injection, nivolumab, 1 mg	23,780	$20	$570.7K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	13,320	$40	$479.5K
A9607	Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie	2,400	$190	$460.8K
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	6,930	$40	$263.3K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	240	$1,000	$236.1K
A9596	Gallium ga-68 gozetotide, diagnostic, (illuccix), 1 millicurie	120	$1,130	$139.1K
J0897	Injection, denosumab, 1 mg	7,440	$20	$133.9K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	3,350	$30	$113.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	960	$90	$87.4K

Showing 1–10 of 132

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 132 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arkansas Distribution

Matthew Lockwood — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arkansas

Full comparison — all codes billed, vs. state median

132 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	18	40	20,700	$40	$896.3K
A9607	2	10	3,310	$200	$656.3K
J9299	7	30	15,660	$20	$432.9K
J9144	2	10	10,530	$40	$361.9K
J1561	6	10	5,930	$40	$216.4K
Q5115	7	20	2,800	$30	$95.9K
J0897	32	160	2,580	$20	$89.7K
A9596	3	10	80	$850	$87.3K
78815	23	100	90	$550	$83.7K
J2353	1	10	510	$160	$82.4K

Showing 1–10 of 132

Related Providers

Other providers that share a Tax Identification Number (TIN) with Matthew Lockwood, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
North Shore Hematology Oncology Associates PC	NY	Specialist	$0	$61.9M
Highlands Oncology Group PA	AR	Hematology & Oncology Physician	$0	$5.7M
Eric Schaefer	AR	Hematology & Oncology Physician	$3.6M	$0
Patrick Travis	AR	Hematology & Oncology Physician	$3.3M	$0
K'anne Arthur	AR	Hematology & Oncology Physician	$3.2M	$0
Gregory Oakhill	AR	Hematology & Oncology Physician	$2.8M	$0
Stephan Rosenfeld	AR	Hematology & Oncology Physician	$2.3M	$0
J Beck	AR	Hematology & Oncology Physician	$2.2M	$0
Dmitriy Zak	AR	Hematology & Oncology Physician	$2.2M	$0
Mitchell Ross	AR	Hematology & Oncology Physician	$2.2M	$0

Nearby Providers

Other providers in the same ZIP code as Matthew Lockwood, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Sanders, Tompkins, Schiro, Landers And Sanders PLLC	AR	Pediatric Dentistry	$0	$30.4M
Children's Therapy Services, Inc.	AR	Pediatric Physical Therapist	$0	$29.2M
Life Styles Inc.	AR	Case Management Agency	$0	$19.6M
Washington Regional Medical Center	AR	General Acute Care Hospital	$0	$10.9M
Cross Therapy Services, Ltd	AR	Pediatric Occupational Therapist	$0	$5.8M
Medical Associates Of Northwest Arkansas PA	AR	Pediatrics Physician	$0	$5.8M
Oral & Facial Surgery Center PA	AR	Oral and Maxillofacial Surgery (Dentist)	$0	$4.8M
Thomas A. Sarna, Dds PLLC	AR	Oral and Maxillofacial Surgery Clinic/Center	$0	$3.4M
Washington Regional Medical System	AR	Hospitalist Physician	$0	$3.4M
The Therapy Spot,llc	AR	Speech-Language Pathologist	$0	$3.2M

Matthew Lockwood — Billing Profile & Reimbursement Data

Sign up for Matthew Lockwood — Billing Profile & Reimbursement Data policy alerts

Matthew Lockwood — Billing Profile & Reimbursement Data

Sign up for Matthew Lockwood — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References